GlassScriptPhysician profile
Sakuntalai Srinanthakumar
NPI 1740272756
$47,955.66
in general payments reported to CMS, 2019-2025
41 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,602 · 2020: $2,752 · 2021: $4,136 · 2022: $2,568 · 2023: $11K · 2024: $13K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $8,104 · Honoraria: $8,075 · Travel and Lodging: $2,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,400.00 |
| Food and Beverage | $8,104.24 |
| Honoraria | $8,075.00 |
| Travel and Lodging | $2,317.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $29,177.60 | 2022-2025 | Auvelity |
| Abbvie INC. | $2,204.94 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $2,131.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,886.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,340.62 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,256.66 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $1,187.64 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $1,084.22 | 2019-2025 | |
| Amarin Pharma, INC. | $757.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $709.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $688.05 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $586.39 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $559.90 | 2019-2022 | |
| Amgen INC. | $557.07 | 2020-2025 | Repatha, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $446.28 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sakuntalai Srinanthakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.